It is considered localized amyloidosis because it mainly affects the skin and does not invade the organs. Cutaneous amyloidosis causes patches of skin that may appear in abnormal textures and colors.

Cutaneous amyloidosis can be localized or secondary to systemic disease. Localized amyloid deposition can be found microscopically in the presence of a variety of cutaneous tumors, actinic ...

In addition, immunohistochemistry analysis of skin biopsies of patients with primary cutaneous localized amyloidosis (LA and MA) revealed an increase in expression of OSMR beta and IL-31RA ...

Venugopal SB, Muralidhar A. Primary localized cutaneous amyloidosis – a clinicopathological study. Arch Med Health Sci. 2019;7 (1):38-41. Ahmed I, Charles-Holmes R, Black MM.

Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.

Amyloidosis is an intractable disease in which proteins are deposited in tissues. 36 types of such amyloid-based proteins are known so far. One common outcome of amyloidosis is Alzheimer's disease ...

Deep dermal deposits, as present here, are seen in both primary and secondary systemic amyloidosis and nodular localized primary cutaneous amyloid (NLPCA).

Lichen amyloidosis is the most common form of primary localized cutaneous amyloidosis. 1 The cause is unknown, but the condition is thought to be induced by scratching. 2 Owing to its benign nature, ...

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

The method works well in mice with eczema (AD: atopic dermatitis), and a rare genetic skin disease called amyloidosis (FPLCA: familial primary localized cutaneous amyloidosis), for which there's ...

Immunoglobulin light chain amyloidosis is a protein deposition disorder where the precursor protein represents a monoclonal immunoglobulin light or heavy chain.

Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.